Trial Profile
Observational study of safety and effectiveness of NovoMix 30 (biphasic insulin aspart) for the treatment of diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jan 2018
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms IMPROVE
- Sponsors Novo Nordisk
- 15 Jun 2012 Actual initiation date changed from 1 Feb 2006 to 1 Sep 2006 as reported by ClinicalTrials.gov.
- 14 Jan 2009 Actual patient number reported as 58223 by ClinicalTrials.gov.
- 14 Jan 2009 Actual end date reported as November 2008 by ClinicalTrials.gov.